Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
AbstractPassive immunotherapy has emerged as a very promising approach for the treatment of Alzheimer’s disease and other neurodegenerative disorders, which are characterized by the misfolding and deposition of amyloid peptides. On the basis of the amyloid hypothesis, the majority of antibodies in clinical development are directed against amyloid β (Aβ), the primary amyloid component in extracellular plaques. This review focuses on the current status of Aβ antibodies in clinical development, including their characteristics and challenges that came up in clinical trials with these new biological entities (NBEs). Emphasis is placed on the current view of common side effects observed with passive immunotherapy, so-called amyloid-related imaging abnormalities (ARIAs), and potential ways to overcome this issue. Among these new ideas, a special focus is placed on molecules that are directed against post-translationally modified variants of the Aβ peptide, an emerging approach for development of new antibody molecules. View Full-Text
Share & Cite This Article
Schilling, S.; Rahfeld, J.-U.; Lues, I.; Lemere, C.A. Passive Aβ Immunotherapy: Current Achievements and Future Perspectives. Molecules 2018, 23, 1068.
Schilling S, Rahfeld J-U, Lues I, Lemere CA. Passive Aβ Immunotherapy: Current Achievements and Future Perspectives. Molecules. 2018; 23(5):1068.Chicago/Turabian Style
Schilling, Stephan; Rahfeld, Jens-Ulrich; Lues, Inge; Lemere, Cynthia A. 2018. "Passive Aβ Immunotherapy: Current Achievements and Future Perspectives." Molecules 23, no. 5: 1068.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.